Skip to content

Understanding the Eye related changes following eye or head injury

Traumatic Optic Neuropathy Treatment study (TONT study) - TNOT study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/11/059379
Enrollment
30
Registered
2023-11-01
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H470- Disorders of optic nerve, not elsewhere classified

Interventions

Intervention1: Medical treatment with high or megadoses of methylprednisolone: 3 days treatment Intervention2: Recombinant Human Erythropoietin: 3 days treatment Control Intervention1: Medical treatme

Sponsors

Aurolab
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: a) Having indirect traumatic optic neuropathy (with normal eye and fundus exam) b) Trauma to treatment interval of 2 weeks and less

Exclusion criteria

Exclusion criteria: a) Direct optic neuropathy b) Glaucoma c) Any retinopathy d) Globe laceration e) Hypertension f) Polycythaemia g) Creatinine more than 3 mg/dl, h) Patients who have received any other form of treatment for their traumatic optic neuropathy

Design outcomes

Primary

MeasureTime frame
Number of Participants with Change/Improvement Visual Acuity From the Baseline [Time Frame: Change from baseline at least 3 months after treatment]Timepoint: 3 months

Secondary

MeasureTime frame
Relative Afferent Pupillary Defect, Color Vision, Side EffectsTimepoint: 3 months

Countries

India

Contacts

Public ContactDr Kowsalya Akkayasamy

Aravind Eye Hospital and Postgraduate Institute of Ophthalmology

dr.kowsalya@aravind.org914524356100

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026